These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27362833)

  • 1. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
    Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
    MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
    Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
    Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
    J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Comprehensive Online Two-Dimensional Liquid Chromatography/Mass Spectrometry Using Hydrophilic Interaction and Reversed-Phase Separations for Rapid and Deep Profiling of Therapeutic Antibodies.
    Stoll DR; Harmes DC; Staples GO; Potter OG; Dammann CT; Guillarme D; Beck A
    Anal Chem; 2018 May; 90(9):5923-5929. PubMed ID: 29614857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
    Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC
    Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic capillary electrophoresis - mass spectrometry for rapid charge-variant and glycoform assessment of monoclonal antibody biosimilar candidates.
    Cageling R; Carillo S; Boumeester AJ; Lubbers-Geuijen K; Bones J; Jooß K; Somsen GW
    J Pharm Biomed Anal; 2024 Sep; 248():116301. PubMed ID: 38901155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High resolution two-dimensional liquid chromatography coupled with mass spectrometry for robust and sensitive characterization of therapeutic antibodies at the peptide level.
    Stoll DR; Lhotka HR; Harmes DC; Madigan B; Hsiao JJ; Staples GO
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Dec; 1134-1135():121832. PubMed ID: 31790917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
    Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The versatility of heart-cutting and comprehensive two-dimensional liquid chromatography in monoclonal antibody clone selection.
    Sandra K; Steenbeke M; Vandenheede I; Vanhoenacker G; Sandra P
    J Chromatogr A; 2017 Nov; 1523():283-292. PubMed ID: 28668371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection.
    Stoll D; Danforth J; Zhang K; Beck A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():51-60. PubMed ID: 27267072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct identification of rituximab main isoforms and subunit analysis by online selective comprehensive two-dimensional liquid chromatography-mass spectrometry.
    Stoll DR; Harmes DC; Danforth J; Wagner E; Guillarme D; Fekete S; Beck A
    Anal Chem; 2015 Aug; 87(16):8307-15. PubMed ID: 26145446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
    Tsuda M; Otani Y; Yonezawa A; Masui S; Ikemi Y; Denda M; Sato Y; Nakagawa S; Omura T; Imai S; Nakagawa T; Hayakari M; Matsubara K
    Biol Pharm Bull; 2018 Nov; 41(11):1716-1721. PubMed ID: 30158337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.
    Dyck YFK; Rehm D; Winkler K; Sandig V; Jabs W; Parr MK
    J Pharm Biomed Anal; 2023 Oct; 235():115596. PubMed ID: 37540995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
    Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
    MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
    Xie H; Chakraborty A; Ahn J; Yu YQ; Dakshinamoorthy DP; Gilar M; Chen W; Skilton SJ; Mazzeo JR
    MAbs; 2010; 2(4):379-94. PubMed ID: 20458189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
    Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
    BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.